ZHONGZHI PHARMACEUTICAL HOLDINGS LIMITED

Zhongzhi Pharmaceutical Holdings Limited

3737

KYG989611085

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 08:12:00 13/01/2026 am IST			5-day change	1st Jan Change
0.7600 ^HKD	-7.32%		-2.56%	+35.71%

26/25/26	Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
18/25/18	Zhongzhi pharmaceutical expects 90% decrease in HY net profit	RE

Zhongzhi Pharmaceutical Holdings Plans to Unwind Contractual Agreements to Directly Hold Control Over Subsidiary

Published on 12/06/2024 at 04:08 pm IST - Modified on 12/06/2024 at 04:09 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Zhongzhi Pharmaceutical Holdings Limited

26/25/26	Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
18/25/18	Zhongzhi pharmaceutical expects 90% decrease in HY net profit	RE
18/25/18	Zhongzhi Pharmaceutical Warns of 90% Drop in H1 Profit	MT
18/25/18	Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2025	CI
13/25/13	Zhongzhi Pharmaceutical Holdings Limited Approves Dividend	CI
10/25/10	Zhongzhi Pharmaceutical Holdings Limited Announces Board and Committee Changes, Effective 10 April 2025	CI
26/25/26	Zhongzhi Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2024, Payable on 19 June 2025	CI
26/25/26	Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/25/17	Zhongzhi Pharmaceutical Expects Profit to Plunge 45% in 2024	MT
17/25/17	Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2024	CI
24/24/24	Zhongzhi Pharmaceutical Invests in US Biotech Firm to Advance Alzheimer's Treatment	MT
06/24/06	Zhongzhi Pharmaceutical Holdings Plans to Unwind Contractual Agreements to Directly Hold Control Over Subsidiary	MT
09/24/09	Zhongzhi Pharmaceutical Holdings Limited Announces Resignation of Peng Zhiyun as Non-Executive Director	CI
23/24/23	Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2024	CI
12/24/12	Zhongzhi Pharmaceutical Warns of 40% Drop in H1 Profit	MT
12/24/12	Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2024	CI
17/24/17	Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Final Dividend	CI
25/24/25	Zhongzhi Pharmaceutical's Attributable Jumps in 2023	MT
22/24/22	Zhongzhi Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 13 June 2024	CI
22/24/22	Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
26/24/26	Zhongzhi Pharmaceutical Expects Over 50% Surge in 2023 Profit	MT
25/24/25	Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023	CI
13/23/13	Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend	CI
24/23/24	Zhongzhi Pharmaceutical’s Profit Up 75% in H1	MT
23/23/23	Zhongzhi Pharmaceutical Holdings Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 2 November 2023	CI

Chart Zhongzhi Pharmaceutical Holdings Limited

Duration

Period

Chart Zhongzhi Pharmaceutical Holdings Limited

3737: Dynamic Chart

Zhongzhi Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceutical products. The Company's products comprise Chinese patent medicines and decoction pieces, mainly consisting of traditional decoction pieces and modern decoction pieces. The Company operates through two segments, including Pharmaceutical Manufacturing segment and Operation of Chain Pharmacies segment. The Company owns brands such as Zhongzhi and Cao Jinghua. The Company's product series also comprises PoBiCaoBen and ZhongChengYao. The Company mainly conducts its businesses in the domestic market.

Employees

2,488

Sector

Pharmaceuticals

Calendar

19/03 - Q4 2025 Earnings Release (Projected)

More about the company